469 related articles for article (PubMed ID: 21717224)
1. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.
Moore L; Fan D; Basu R; Kandalam V; Kassiri Z
Heart Fail Rev; 2012 Sep; 17(4-5):693-706. PubMed ID: 21717224
[TBL] [Abstract][Full Text] [Related]
2. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.
Vanhoutte D; Heymans S
J Mol Cell Cardiol; 2010 Mar; 48(3):445-53. PubMed ID: 19799912
[TBL] [Abstract][Full Text] [Related]
3. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Krebber MM; van Dijk CGM; Vernooij RWM; Brandt MM; Emter CA; Rau CD; Fledderus JO; Duncker DJ; Verhaar MC; Cheng C; Joles JA
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937927
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases: pathways of induction by bioactive molecules.
Tsuruda T; Costello-Boerrigter LC; Burnett JC
Heart Fail Rev; 2004 Jan; 9(1):53-61. PubMed ID: 14739768
[TBL] [Abstract][Full Text] [Related]
5. Cardiac remodeling and failure From molecules to man (Part II).
Fedak PW; Verma S; Weisel RD; Li RK
Cardiovasc Pathol; 2005; 14(2):49-60. PubMed ID: 15780796
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression.
Polyakova V; Hein S; Kostin S; Ziegelhoeffer T; Schaper J
J Am Coll Cardiol; 2004 Oct; 44(8):1609-18. PubMed ID: 15489093
[TBL] [Abstract][Full Text] [Related]
7. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
[TBL] [Abstract][Full Text] [Related]
8. Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007.
Graham HK; Horn M; Trafford AW
Acta Physiol (Oxf); 2008 Sep; 194(1):3-21. PubMed ID: 18577182
[TBL] [Abstract][Full Text] [Related]
9. The role of TIMPs in regulation of extracellular matrix proteolysis.
Arpino V; Brock M; Gill SE
Matrix Biol; 2015; 44-46():247-54. PubMed ID: 25805621
[TBL] [Abstract][Full Text] [Related]
10. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
Li YY; McTiernan CF; Feldman AM
Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
[TBL] [Abstract][Full Text] [Related]
11. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats.
Iwanaga Y; Aoyama T; Kihara Y; Onozawa Y; Yoneda T; Sasayama S
J Am Coll Cardiol; 2002 Apr; 39(8):1384-91. PubMed ID: 11955860
[TBL] [Abstract][Full Text] [Related]
12. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.
Pauschinger M; Chandrasekharan K; Schultheiss HP
Heart Fail Rev; 2004 Jan; 9(1):21-31. PubMed ID: 14739765
[TBL] [Abstract][Full Text] [Related]
13. Extracellular matrix remodeling during the progression of volume overload-induced heart failure.
Hutchinson KR; Stewart JA; Lucchesi PA
J Mol Cell Cardiol; 2010 Mar; 48(3):564-9. PubMed ID: 19524591
[TBL] [Abstract][Full Text] [Related]
14. Role of Matrix Metalloproteinases in Degenerative Kidney Disorders.
Narula S; Tandon C; Tandon S
Curr Med Chem; 2018; 25(15):1805-1816. PubMed ID: 29210632
[TBL] [Abstract][Full Text] [Related]
15. [Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy].
Pauschinger M; Chandrasekharan K; Li J; Schwimmbeck PL; Noutsias M; Schultheiss HP
Herz; 2002 Nov; 27(7):677-82. PubMed ID: 12439639
[TBL] [Abstract][Full Text] [Related]
16. Ovarian tissue remodeling: role of matrix metalloproteinases and their inhibitors.
Smith MF; Ricke WA; Bakke LJ; Dow MP; Smith GW
Mol Cell Endocrinol; 2002 May; 191(1):45-56. PubMed ID: 12044918
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis.
Shan L; Wang F; Zhai D; Meng X; Liu J; Lv X
Biomed Pharmacother; 2023 May; 161():114472. PubMed ID: 37002573
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
Spinale FG
Circ Res; 2002 Mar; 90(5):520-30. PubMed ID: 11909815
[TBL] [Abstract][Full Text] [Related]
19. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
Mukherjee R; Herron AR; Lowry AS; Stroud RE; Stroud MR; Wharton JM; Ikonomidis JS; Crumbley AJ; Spinale FG; Gold MR
Am J Cardiol; 2006 Feb; 97(4):532-7. PubMed ID: 16461051
[TBL] [Abstract][Full Text] [Related]
20. Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors.
Kassiri Z; Khokha R
Thromb Haemost; 2005 Feb; 93(2):212-9. PubMed ID: 15711735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
